title: Radiation therapy for older adults with glioblastoma: radical treatment, palliative treatment, or no treatment at all?
abstract: The incidence of glioblastoma in older adults has increased over the last few decades. Current treatment includes surgery, radiotherapy, and chemotherapy, but optimal disease management remains a matter of debate. Both standard (60 Gy in 30 daily fractions) and hypofractionated radiotherapy (30-40 Gy in 10-15 daily fractions) have been employed with a similar survival benefit. Recent randomized studies indicate that chemotherapy with the alkylating agent temozolomide is a safe and effective therapeutic option for patients aged 60 years or older with newly diagnosed glioblastoma, suggesting that it should be a sufficient treatment for patients presenting with a methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter gene. The addition of concomitant temozolomide chemotherapy, adjuvant temozolomide chemotherapy, or both to postoperative radiotherapy, which is the standard treatment for adults with glioblastoma, has been associated with a survival benefit for older patients with a good performance status; however, aggressive treatment in this population may be associated with a high risk of neurological toxicity and deterioration of quality of life. Survival stratification according to age, MGMT promoter methylation status, and neurological status may be useful for clinical decision making and designing randomized trials for adequately evaluating the optimal combination of radiotherapy and chemotherapy for older patients with glioblastoma.
authors.affiliation: Department of Radiation Oncology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy, giuseppe.minniti@ospedalesantandrea.it.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Minniti
authors.forename: Riccardo Maurizi
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000532:radiotherapy*; D005909:Glioblastoma / Q000532:radiotherapy*; D006801:Humans; D010166:Palliative Care; D016896:Treatment Outcome
references.citation: Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):93-9
references.pmid: 22079725
references.citation: Clin Oncol (R Coll Radiol). 1997;9(1):20-4
references.pmid: 9039809
references.citation: J Neurooncol. 2014 Jan;116(2):299-306
references.pmid: 24173683
references.citation: J Neurooncol. 1997 Jul;33(3):201-4
references.pmid: 9195491
references.citation: Br J Neurosurg. 2002 Aug;16(4):343-7
references.pmid: 12389886
references.citation: J Natl Cancer Inst. 1994 Dec 7;86(23):1766-70
references.pmid: 7966414
references.citation: Oncology (Williston Park). 1998 Feb;12(2):233-40; discussion 240, 246
references.pmid: 9507524
references.citation: J Neurooncol. 2008 Aug;89(1):97-103
references.pmid: 18398569
references.citation: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92
references.pmid: 17967509
references.citation: Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9
references.pmid: 8040031
references.citation: J Clin Oncol. 2004 May 1;22(9):1583-8
references.pmid: 15051755
references.citation: Clin Neurol Neurosurg. 2013 Oct;115(10):2142-6
references.pmid: 23993314
references.citation: Neurology. 2009 Nov 3;73(18):1509-10
references.pmid: 19884580
references.citation: Radiother Oncol. 2010 Dec;97(3):382-6
references.pmid: 20850883
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2109-17
references.pmid: 11956272
references.citation: Cancers (Basel). 2013 Sep 24;5(3):1177-98
references.pmid: 24202340
references.citation: Cancer. 2003 Feb 1;97(3):657-62
references.pmid: 12548608
references.citation: N Engl J Med. 1999 Dec 30;341(27):2061-7
references.pmid: 10615079
references.citation: Radiother Oncol. 2005 May;75(2):210-6
references.pmid: 15885825
references.citation: Cancer. 2009 Aug 1;115(15):3512-8
references.pmid: 19514084
references.citation: Radiother Oncol. 1994 Nov;33(2):113-6
references.pmid: 7535939
references.citation: J Neurooncol. 2012 Sep;109(2):391-7
references.pmid: 22688802
references.citation: J Neurooncol. 2011 Apr;102(2):311-6
references.pmid: 20686820
references.citation: Lancet Oncol. 2012 Sep;13(9):916-26
references.pmid: 22877848
references.citation: Radiother Oncol. 2003 May;67(2):177-82
references.pmid: 12812848
references.citation: Lancet. 1982 Apr 17;1(8277):885-7
references.pmid: 6122104
references.citation: J Neurooncol. 1999 Jun;43(2):187-93
references.pmid: 10533732
references.citation: Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):981-7
references.pmid: 9869219
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Lancet Oncol. 2012 Jul;13(7):707-15
references.pmid: 22578793
references.citation: Cancer. 2003 May 1;97(9):2262-6
references.pmid: 12712481
references.citation: Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):285-91
references.pmid: 23642624
references.citation: N Engl J Med. 2007 Apr 12;356(15):1527-35
references.pmid: 17429084
references.citation: Cancer. 2004 May 15;100(10):2208-14
references.pmid: 15139066
references.citation: J Neurooncol. 2008 May;88(1):97-103
references.pmid: 18250965
references.citation: Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):977-80
references.pmid: 9869218
references.citation: J Neurooncol. 2009 Jan;91(1):95-100
references.pmid: 18758912
references.citation: Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
references.pmid: 23095881
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3050-5
references.pmid: 21709196
references.citation: Strahlenther Onkol. 2012 Feb;188(2):154-9
references.pmid: 22231634
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009